About all manner of pharmaceutical scientific misconduct, bad science, and related curious incidents. If you're not outraged, you're not paying attention.
Tuesday, January 15, 2008
Ezetimibe Zetia Vytorin - Headless Chicken Award
The Ezetimibe data are out (all those thousands of un-analyzed images that formed the excuse for non release of the results were obviously analyzed at the speed of light). From the WSJ "The long-delayed and much-speculated-about data from Merck and Schering-Plough’s Enhance study comparing whether a combination of Zetia and Zocor works better than Zocor alone were finally released today."
It's a bummer. Time for the first Headless Chicken award of 2008.
"ENHANCE lacked many of the safeguards that many clinical trials have, and it seems to have been plagued by problems. Studies often have pre-specified committees that deal with any problems that come up. ENHANCE didn't, and as a result when things went wrong, the companies had to put together a confidential panel on the fly. (See: " Schering and Merck's Secret Panel")"
Yes ENHANCE lacked safeguards - like that the study was carried out by Merck and Schering.
4 comments:
From Forbes today:
"ENHANCE lacked many of the safeguards that many clinical trials have, and it seems to have been plagued by problems. Studies often have pre-specified committees that deal with any problems that come up. ENHANCE didn't, and as a result when things went wrong, the companies had to put together a confidential panel on the fly. (See: " Schering and Merck's Secret Panel")"
Yes ENHANCE lacked safeguards - like that the study was carried out by Merck and Schering.
See
http://www.brandweeknrx.com/2008/01/schering-plou-1.html
Schering-Plough President dumped $28 million SGP stock before Vytorin controversy erupted.
Hi Aubrey,
I sent Dr. Kastelein a link to your blog. He got a kick out of it. Keep up the good work!
Marilyn
Thanks - I wonder whether he will author the paper?
Post a Comment